These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

In the QUILT 106 trial, CD19-targeted high-affinity natural killer (t-haNK) cells are being tested initially ... in combination with the company’s IL-15 superagonist (N-803; ANKTIVA®) and ...

The first clinical program to go over involves the use of ImmunityBio's CAR-NK cell therapy CD19 t-haNK ... the same time period. Even though IL-15 ANKTIVA was shown to do well in treating ...

Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential of the company’s CAR-NK cell therapy ...

Safety and accessibility are paramount in autoimmune disease, and we believe that an off-the-shelf, engineered NK cell therapy ... for enhanced cell targeting and a proprietary, membrane-bound form of ...

NCT01287104 A Phase I study of NK cell infusion following allogeneic ... Consortium NCT01337544 Haploidentical stem cell transplantation and IL-15 NK cell infusion for paediatric refractory ...

mAb technology has the capability to create distinct agents that can bind to virtually any antigen on the tumor cell surface ... cell transplantation and IL-15 NK cell infusion for paediatric ...